-
1
-
-
0015383455
-
Apoptosis: A basic biological phenomenon with wideranging implications in tissue kinetics
-
Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer 1972;26:239-57
-
(1972)
Br J Cancer
, vol.26
, pp. 239-257
-
-
Kerr, J.F.R.1
Wyllie, A.H.2
Currie, A.R.3
-
2
-
-
0027255942
-
Apoptosis and disease
-
Carson DA, Ribiero JM. Apoptosis and disease. Lancet 1993;341:1251-4
-
(1993)
Lancet
, vol.341
, pp. 1251-1254
-
-
Carson, D.A.1
Ribiero, J.M.2
-
3
-
-
0030016233
-
The role of apoptosis in the pathogenesis and treatment of disease
-
Solary E, Dubrez L, Eymin B. The role of apoptosis in the pathogenesis and treatment of disease. Eur Respir J 1996;9:1293-305
-
(1996)
Eur Respir J
, vol.9
, pp. 1293-1305
-
-
Solary, E.1
Dubrez, L.2
Eymin, B.3
-
4
-
-
0036088471
-
IAP proteins: Blocking the road to death's door
-
Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10
-
(2002)
Nat Rev Mol Cell Biol
, vol.3
, pp. 401-410
-
-
Salvesen, G.S.1
Duckett, C.S.2
-
5
-
-
77954930632
-
IAPs: From caspase inhibitors to modulators of NF-kB, inflammation, and cancer
-
Gyrd-Hansen M, Meier P. IAPs: From caspase inhibitors to modulators of NF-kB, inflammation, and cancer. Nat Rev Cancer 2010;10:561-74
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 561-574
-
-
Gyrd-Hansen, M.1
Meier, P.2
-
6
-
-
84884254106
-
IAP proteins as targets for drug development in oncology
-
Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Targets Ther 2013;6:1285-304
-
(2013)
Onco Targets Ther
, vol.6
, pp. 1285-1304
-
-
Dubrez, L.1
Berthelet, J.2
Glorian, V.3
-
7
-
-
0034905394
-
XIAP: Apoptotic brake and promising therapeutic target
-
Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001;6:253-61
-
(2001)
Apoptosis
, vol.6
, pp. 253-261
-
-
Holcik, M.1
Gibson, H.2
Korneluk, R.G.3
-
8
-
-
17144438370
-
Expression and prognostic significance of IAPfamily genes in human cancers and myeloid leukemias
-
Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAPfamily genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1796-1803
-
-
Tamm, I.1
Kornblau, S.M.2
Segall, H.3
-
9
-
-
0142188706
-
Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy
-
Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res 2003;63:6815-24
-
(2003)
Cancer Res
, vol.63
, pp. 6815-6824
-
-
Yang, L.1
Cao, Z.2
Yan, H.3
Wood, W.C.4
-
10
-
-
35948950248
-
The inhibitor of apoptosis proteins as therapeutic targets in cancer
-
Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5995-6000
-
-
Vucic, D.1
Fairbrother, W.J.2
-
11
-
-
0034710649
-
Structural and biochemical basis of apoptotic activation by Smac/DIABLO
-
Chai J, Du C, Wu JW, et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000;406:855-62
-
(2000)
Nature
, vol.406
, pp. 855-862
-
-
Chai, J.1
Du, C.2
Wu, J.W.3
-
12
-
-
0034700495
-
Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain
-
Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000;408:1004-8
-
(2000)
Nature
, vol.408
, pp. 1004-1008
-
-
Liu, Z.1
Sun, C.2
Olejniczak, E.T.3
-
13
-
-
0034700491
-
Structural basis of IAP recognition by Smac/DIABLO
-
Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408:1008-12
-
(2000)
Nature
, vol.408
, pp. 1008-1012
-
-
Wu, G.1
Chai, J.2
Suber, T.L.3
-
15
-
-
84906938621
-
Small-molecule Smac mimetics as new cancer therapeutics
-
Bai L, Smith DC, Wang S. Small-molecule Smac mimetics as new cancer therapeutics. Pharmacol Ther 2014;144:82-95
-
(2014)
Pharmacol Ther
, vol.144
, pp. 82-95
-
-
Bai, L.1
Smith, D.C.2
Wang, S.3
-
16
-
-
69349104331
-
Structural basis for bivalent Smacmimetics recognition in the IAP protein family
-
Cossu F, Milani M, Mastrangelo E, et al. Structural basis for bivalent Smacmimetics recognition in the IAP protein family. J Mol Biol 2009;392:630-44
-
(2009)
J Mol Biol
, vol.392
, pp. 630-644
-
-
Cossu, F.1
Milani, M.2
Mastrangelo, E.3
-
17
-
-
37049019494
-
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP
-
Sun H, Nikolovska-Coleska Z, Lu J, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 2007;129:15279-94
-
(2007)
J Am Chem Soc
, vol.129
, pp. 15279-15294
-
-
Sun, H.1
Nikolovska-Coleska, Z.2
Lu, J.3
-
18
-
-
84869209741
-
Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic
-
Cossu F, Milani M, Vachette P, et al. Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic. PLoS One 2012;7:e49527
-
(2012)
PLoS One
, vol.7
, pp. e49527
-
-
Cossu, F.1
Milani, M.2
Vachette, P.3
-
19
-
-
36048982462
-
Smac mimetics and TNFalpha: A dangerous liaison?
-
Wu H, Tschopp J, Lin SC. Smac mimetics and TNFalpha: a dangerous liaison? Cell 2007;131:655-8
-
(2007)
Cell
, vol.131
, pp. 655-658
-
-
Wu, H.1
Tschopp, J.2
Lin, S.C.3
-
20
-
-
67650787318
-
Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists
-
Ndubaku C, Varfolomeev E, Wang L, et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol 2009;4:557-66
-
(2009)
ACS Chem Biol
, vol.4
, pp. 557-566
-
-
Ndubaku, C.1
Varfolomeev, E.2
Wang, L.3
-
21
-
-
36048999753
-
IAP antagonists induce autoubiquitination of c-IAPs. NFkappaB activation, and TNFalphadependent apoptosis
-
Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NFkappaB activation, and TNFalphadependent apoptosis. Cell 2007;131:669-81
-
(2007)
Cell
, vol.131
, pp. 669-681
-
-
Varfolomeev, E.1
Blankenship, J.W.2
Wayson, S.M.3
-
22
-
-
84872398313
-
Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNFalpha pharmacology
-
Erickson RI, Tarrant J, Cain G, et al. Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNFalpha pharmacology. Toxicol Sci 2013;131:247-58
-
(2013)
Toxicol Sci
, vol.131
, pp. 247-258
-
-
Erickson, R.I.1
Tarrant, J.2
Cain, G.3
-
23
-
-
84904612262
-
X-linked inhibitor of apoptosis protein-a critical death resistance regulator and therapeutic target for personalized cancer therapy
-
Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein-a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol 2014;4:197
-
(2014)
Front Oncol
, vol.4
, pp. 197
-
-
Obexer, P.1
Ausserlechner, M.J.2
-
24
-
-
84879411444
-
Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP
-
Ardecky RJ, Welsh K, Finlay D, et al. Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP. Bioorg Med Chem Lett 2013;23:4253-7
-
(2013)
Bioorg Med Chem Lett
, vol.23
, pp. 4253-4257
-
-
Ardecky, R.J.1
Welsh, K.2
Finlay, D.3
-
25
-
-
84886470433
-
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain
-
Kester RF, Donnell AF, Lou Y, et al. Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain. J Med Chem 2013;56:7788-803
-
(2013)
J Med Chem
, vol.56
, pp. 7788-7803
-
-
Kester, R.F.1
Donnell, A.F.2
Lou, Y.3
-
26
-
-
84886533505
-
Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain
-
Donnell AF, Michoud C, Rupert KC, et al. Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain. J Med Chem 2013;56:7772-87
-
(2013)
J Med Chem
, vol.56
, pp. 7772-7787
-
-
Donnell, A.F.1
Michoud, C.2
Rupert, K.C.3
-
27
-
-
0034616945
-
Smac, a mitochondrial protein that promotes cytochrome c dependent caspase activation by eliminating IAP inhibition
-
Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42
-
(2000)
Cell
, vol.102
, pp. 33-42
-
-
Du, C.1
Fang, M.2
Li, Y.3
-
28
-
-
0034616942
-
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
-
Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53
-
(2000)
Cell
, vol.102
, pp. 43-53
-
-
Verhagen, A.M.1
Ekert, P.G.2
Pakusch, M.3
-
30
-
-
80054122612
-
The discovery and development of Smac mimetics-small-molecule antagonists of the inhibitor of apoptosis proteins
-
Condon SM. The discovery and development of Smac mimetics-small-molecule antagonists of the inhibitor of apoptosis proteins Annu Rep Med Chem. 2011;46:211-26
-
(2011)
Annu Rep Med Chem
, vol.46
, pp. 211-226
-
-
Condon, S.M.1
-
31
-
-
84925546890
-
Targeting the inhibitor of apoptosis protein BIR3 binding domains
-
Jaquith JB. Targeting the inhibitor of apoptosis protein BIR3 binding domains. Pharm Pat Anal 2014;3:297-312
-
(2014)
Pharm Pat Anal
, vol.3
, pp. 297-312
-
-
Jaquith, J.B.1
-
32
-
-
76149118435
-
Small-molecule pan-IAP antagonists: A patent review
-
Flygare JA, Fairbrother WJ. Small-molecule pan-IAP antagonists: a patent review. Expert Opin Ther Pat 2010;20:251-67
-
(2010)
Expert Opin Ther Pat
, vol.20
, pp. 251-267
-
-
Flygare, J.A.1
Fairbrother, W.J.2
-
34
-
-
84935013137
-
-
Note: additional searches of livin or survivin only yielded one patent application between 2010-2014 that exemplified small molecule inhibitors of survivin dimerization WO083505
-
Note: additional searches of "livin" or "survivin" only yielded one patent application between 2010-2014 that exemplified small molecule inhibitors of survivin dimerization. See; The Trustees of the University of Pennsylvania. Method of treating cancer using a survivin inhibitor. WO083505; 2010
-
(2010)
The Trustees of the University of Pennsylvania. Method of Treating Cancer Using A Survivin Inhibitor
-
-
-
35
-
-
84934968450
-
-
Aegera Therapeutics, Inc WO098904
-
Aegera Therapeutics, Inc. IAP BIR domain binding compounds. WO098904; 2011
-
(2011)
IAP BIR Domain Binding Compounds
-
-
-
36
-
-
21044441651
-
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo
-
Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br J Cancer 2005;25:1430-41
-
(2005)
Br J Cancer
, vol.25
, pp. 1430-1441
-
-
Pukac, L.1
Kanakaraj, P.2
Humphreys, R.3
-
37
-
-
84934998958
-
AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma model
-
Chessari G, Maria A, Buck I, et al. AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma model. Cancer Res 2013;73(8 Suppl):2944
-
(2013)
Cancer Res
, vol.73
, Issue.8
, pp. 2944
-
-
Chessari, G.1
Maria, A.2
Buck, I.3
-
43
-
-
84934961538
-
-
Genentech Inc US0172264
-
Genentech, Inc. Inhibitors of IAP. US0172264; 2013
-
(2013)
Inhibitors of IAP
-
-
-
44
-
-
84934906597
-
-
Genentech Inc WO017035
-
Genentech, Inc. Inhibitors of IAP. WO017035; 2010
-
(2010)
Inhibitors of IAP
-
-
-
46
-
-
59449104825
-
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
-
Jin H, Yang R, Ross J, et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 2008;14:7733-40
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7733-7740
-
-
Jin, H.1
Yang, R.2
Ross, J.3
-
55
-
-
84934969766
-
-
Tetralogic Pharmaceuticals Corp WO033531
-
Tetralogic Pharmaceuticals Corp. IAP inhibitors. WO033531; 2010
-
(2010)
IAP Inhibitors
-
-
-
56
-
-
84934969766
-
-
Tetralogic Pharmaceuticals Corp WO138496
-
Tetralogic Pharmaceuticals Corp. IAP inhibitors. WO138496; 2010
-
(2010)
IAP Inhibitors
-
-
-
57
-
-
84934969766
-
-
Tetralogic Pharmaceuticals Corp WO138666
-
Tetralogic Pharmaceuticals Corp. IAP inhibitors. WO138666; 2010
-
(2010)
IAP Inhibitors
-
-
-
58
-
-
84934901729
-
-
Tetralogic Pharmaceuticals Corp WO068926
-
Tetralogic Pharmaceuticals Corp. IAP inhibitors. WO068926; 2011
-
(2011)
IAP Inhibitors
-
-
-
59
-
-
84934961360
-
-
Aegera Therapeutics, Inc WO031171
-
Aegera Therapeutics, Inc. IAP BIR domain binding compounds. WO031171; 2010
-
(2010)
IAP BIR Domain Binding Compounds
-
-
-
60
-
-
84935027598
-
-
Aegera Therapeutics, Inc US0141496
-
Aegera Therapeutics, Inc. IAP BIR domain binding compounds. US0141496; 2012
-
(2012)
IAP BIR Domain Binding Compounds
-
-
-
64
-
-
84934890875
-
-
Bristol-Myers Squibb Co US0338081
-
Bristol-Myers Squibb Co. IAP antagonists. US0338081; 2013
-
(2013)
IAP Antagonists
-
-
-
65
-
-
84934948584
-
-
Bristol-Myers Squibb Co WO055461
-
Bristol-Myers Squibb Co. IAP antagonists. WO055461; 2014
-
(2014)
IAP Antagonists
-
-
-
66
-
-
84934948584
-
-
Bristol-Myers Squibb Co WO047024
-
Bristol-Myers Squibb Co. IAP antagonists. WO047024; 2014
-
(2014)
IAP Antagonists
-
-
-
67
-
-
84934948584
-
-
Bristol-Myers Squibb Co WO011712
-
Bristol-Myers Squibb Co. IAP antagonists. WO011712; 2014
-
(2014)
IAP Antagonists
-
-
-
68
-
-
84934948584
-
-
Bristol-Myers Squibb Co WO025759
-
Bristol-Myers Squibb Co. IAP antagonists. WO025759; 2014
-
(2014)
IAP Antagonists
-
-
-
70
-
-
84891297614
-
Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)
-
Hennessy EJ, Adam A, Aquila BM, et al. Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582). J Med Chem 2013;56:9897-919
-
(2013)
J Med Chem
, vol.56
, pp. 9897-9919
-
-
Hennessy, E.J.1
Adam, A.2
Aquila, B.M.3
-
71
-
-
84935030132
-
-
Joyant Pharmaceuticals WO059763
-
Joyant Pharmaceuticals. Dimeric Smac mimetics. WO059763; 2011
-
(2011)
Dimeric Smac Mimetics
-
-
-
72
-
-
84984558764
-
Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells
-
Chen KF, Lin JP, Shiau CW, et al. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol 2012;84:268-77
-
(2012)
Biochem Pharmacol
, vol.84
, pp. 268-277
-
-
Chen, K.F.1
Lin, J.P.2
Shiau, C.W.3
-
79
-
-
79954504195
-
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment
-
Cai Q, Sun H, Peng Y, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011;54:2714-26
-
(2011)
J Med Chem
, vol.54
, pp. 2714-2726
-
-
Cai, Q.1
Sun, H.2
Peng, Y.3
-
81
-
-
0037075812
-
Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors
-
Hennequin LF, Stokes Elaine SE, Thomas A, et al. Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. J Med Chem 2002;45:1300-12
-
(2002)
J Med Chem
, vol.45
, pp. 1300-1312
-
-
Hennequin, L.F.1
Stokes Elaine, S.E.2
Thomas, A.3
-
82
-
-
58149333768
-
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novelT854A mutation in a patient with EGFRMutant lung adenocarcinoma
-
Bean J, Riely GJ, Balak M, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novelT854A mutation in a patient with EGFRMutant lung adenocarcinoma. Clin Cancer Res 2008;14:7519-25
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7519-7525
-
-
Bean, J.1
Riely, G.J.2
Balak, M.3
-
83
-
-
0035939330
-
Studies leading to the identification of ZD1839 (iressa): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
-
Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-14
-
(2001)
Bioorg Med Chem Lett
, vol.11
, pp. 1911-1914
-
-
Barker, A.J.1
Gibson, K.H.2
Grundy, W.3
-
84
-
-
0035553174
-
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo
-
Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94
-
(2001)
Mol Cancer Ther
, vol.1
, pp. 85-94
-
-
Rusnak, D.W.1
Lackey, K.2
Affleck, K.3
-
86
-
-
84927563731
-
AD-O53.2-a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L Invest
-
Pieczykolan JS, Kubiński K, Maslyk M, et al. AD-O53.2-a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L Invest. New Drugs 2014;32:1155-66
-
(2014)
New Drugs
, vol.32
, pp. 1155-1166
-
-
Pieczykolan, J.S.1
Kubiński, K.2
Maslyk, M.3
-
87
-
-
84935015973
-
Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinumrefractory epithelial ovarian cancer (EOC) [abstract number 444]. Preliminary results of a Phase i doseescalation study
-
Presented at 18-21 November Barcelona, Spain. Poster Available from
-
Tourneau CL, Ray-coquard I, Isambert N, et al. Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinumrefractory epithelial ovarian cancer (EOC) [abstract number 444]. Preliminary results of a Phase I doseescalation study. Presented at the 26th Annual EORTC-NCI-AACR Meeting; 18-21 November 2014; Barcelona, Spain. Poster Available from https://www.debiopharm.com/images/stories/files/publications/2014-Debio-1143-in-combination-with-carboplatin.pdf
-
(2014)
The 26th Annual EORTC-NCI-AACR Meeting
-
-
Tourneau, C.L.1
Ray-Coquard, I.2
Isambert, N.3
-
88
-
-
84888591895
-
Learning and confirming with preclinical studies: Modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist
-
Wong H, Gould SE, Budha N, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos 2013;41:2104-13
-
(2013)
Drug Metab Dispos
, vol.41
, pp. 2104-2113
-
-
Wong, H.1
Gould, S.E.2
Budha, N.3
-
89
-
-
84877095096
-
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-a-independent mechanism
-
Allensworth JL, Sauer SJ, Lyerly HK, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-a-independent mechanism. Breast Cancer Res Treat 2013;137:359-71
-
(2013)
Breast Cancer Res Treat
, vol.137
, pp. 359-371
-
-
Allensworth, J.L.1
Sauer, S.J.2
Lyerly, H.K.3
-
90
-
-
84934899572
-
A phase 1b/2a study of birinapant in combination with 5-azacitadine in patients with myelodysplastic syndrome who are näve, refractory to or have relapsed on 5-azacitadine: A preliminary analysis [abstract 3263]
-
Presented at 6-9 December San Francisco, California. Available from
-
Borthakur G, Foran JM, Wang E, et al. A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Näve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis [abstract 3263]. Presented at the 56th Annual American Society of Hematology Annual Meeting and Exposition; 6-9 December 2014; San Francisco, California. Available from: https://ash.confex.com/ash/2014/webprogram/Paper68257.html
-
(2014)
The 56th Annual American Society of Hematology Annual Meeting and Exposition
-
-
Borthakur, G.1
Foran, J.M.2
Wang, E.3
-
91
-
-
84934981674
-
A phase i study using single agent birinapant in patients with relapsed myelodysplastic syndrome and acute myelogenous leukemia [abstract 3758]
-
Presented at 6-9 December San Francisco, California. Available from
-
Frey N, Luger S, Mangan J, et al. A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia [abstract 3758]. Presented at the 56th Annual American Society of Hematology Annual Meeting and Exposition; 6-9 December 2014; San Francisco, California. Available from: https://ash.confex.com/ash/2014/webprogram/Paper75637.html
-
(2014)
The 56th Annual American Society of Hematology Annual Meeting and Exposition
-
-
Frey, N.1
Luger, S.2
Mangan, J.3
-
93
-
-
84856455103
-
Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase i study
-
Sikic B, Eckhardt S, Gallant G, et al. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. J Clin Oncol 2012;29(Suppl):3008
-
(2012)
J Clin Oncol
, vol.29
, pp. 3008
-
-
Sikic, B.1
Eckhardt, S.2
Gallant, G.3
-
94
-
-
84934907317
-
Firstin-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase i study of Debio1143 (AT-406) in patients with advanced cancer: Final results
-
Hurwitz H, Pitot H, Smith D, et al. Firstin-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: final results. J Clin Oncol 2014;32(5s Suppl):abstract 2532
-
(2014)
J Clin Oncol
, vol.32
, Issue.5
-
-
Hurwitz, H.1
Pitot, H.2
Smith, D.3
-
95
-
-
84888591895
-
Learning and confirming with preclinical studies: Modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist
-
Wong H, Gould S, Budha N, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos 2013;41:2104-13
-
(2013)
Drug Metab Dispos
, vol.41
, pp. 2104-2113
-
-
Wong, H.1
Gould, S.2
Budha, N.3
-
96
-
-
84901490248
-
Phase i study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma
-
Tolcher A, Papadopoulos K, Patnaik A, et al. Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. J Clin Oncol 2013;31(Suppl):abstract 2503
-
(2013)
J Clin Oncol
, vol.31
-
-
Tolcher, A.1
Papadopoulos, K.2
Patnaik, A.3
-
97
-
-
84907883684
-
Phase i dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors
-
Infante J, Dees E, Olszanski A, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014;32:3103-10
-
(2014)
J Clin Oncol
, vol.32
, pp. 3103-3110
-
-
Infante, J.1
Dees, E.2
Olszanski, A.3
-
98
-
-
84934924194
-
Phase Ib study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with weekly paclitaxel in patients with advanced solid tumors: Safety and efficacy results, including breast cancer cohort [abstract number: PD5-7]
-
Presented at 10-14 December San Antonio, TX. Available from
-
Dienstmann R, Adamo B, Vidal L, et al. Phase Ib study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with weekly paclitaxel in patients with advanced solid tumors: Safety and efficacy results, including breast cancer cohort [abstract number: PD5-7]. Presented at the 36th Annual San Antonio Breast Cancer Symposium; 10-14 December 2013; San Antonio, TX. Available from: http://www.abstracts2view.com/sabcs13/view. php?nu=SABCS13L-1038
-
(2013)
The 36th Annual San Antonio Breast Cancer Symposium
-
-
Dienstmann, R.1
Adamo, B.2
Vidal, L.3
-
99
-
-
84856418209
-
Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety pharmacokinetics pharmacodynamics and antitumor activity [abstract LB-406]
-
Available from 2-6 Apr Orlando, Florida
-
Amaravadi R, Schilder R, Dy G, et al. Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics and antitumor activity [abstract LB-406]. Available from Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2-6 Apr 2011; Orlando, Florida
-
(2011)
Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research
-
-
Amaravadi, R.1
Schilder, R.2
Dy, G.3
-
100
-
-
84899917603
-
Phase II clinical activity and tolerability of the Smac-mimetic birinapant (TL32711) plus irinotecan in irinotecanrelapsed/refractory metastatic colorectal cancer
-
Senzer N, LoRusso P, Martin L, et al. Phase II clinical activity and tolerability of the Smac-mimetic birinapant (TL32711) plus irinotecan in irinotecanrelapsed/refractory metastatic colorectal cancer. J Clin Oncol 2013;31(Suppl):abstract 3621
-
(2013)
J Clin Oncol
, vol.31
-
-
Senzer, N.1
Lorusso, P.2
Martin, L.3
|